Trial Profile
A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Combination to Insulin Glargine With Metformin in Japanese Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin glargine; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms LIXILAN JP-L
- Sponsors Sanofi
- 11 Jun 2019 Primary endpoint (Change from baseline in HbA1c) has been met, according to the results presented at the 79th Annual Scientific Sessions of the American Diabetes Association
- 11 Jun 2019 Results presented at the 79th Annual Scientific Sessions of the American Diabetes Association
- 15 Oct 2018 Status changed from active, no longer recruiting to completed.